Mavenir Launches Open RAN Intelligent Controller (O-RIC) Offering Enabling Service Differentiation and Network Resource Optimization
10.2.2023 17:00:00 EET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced the availability of its O-RAN alliance Radio Access Network Intelligent Controller (RIC), a next-generation network intelligence offering for Open RAN. Mavenir O-RIC enables the creation of differentiated services through open APIs, which enable intelligent closed-loop end-to-end network tuning to optimize network performance, increase cost efficiency and maximize the user experience. Mavenir’s O-RIC offers Network Intelligence as a Service (NIaaS) that provides deep, fine-grained insights about the network and enables building solutions with advanced state of art intelligence. Open RAN networks can also now generate new class-of-service revenue streams by adaptively reacting in near-real time to dynamic changes in network, traffic, and load patterns. Mavenir’s O-RIC is currently in deployment with two, tier one Communications Service Providers (CSPs).
Traditional RAN networks currently use area wide Self-Organizing Network (SON) models for exercising Radio Resource Management (RRM) and configuration management optimization decisions at a per-cell level. They rely on single control loop, leverage key performance indicators (KPIs) and analytics for such control decisions at non-real time (Non-RT) granularities.
Mavenir’s O-RIC surpasses the capabilities of SON with two control loops:
- Non-RT O-RIC — Typically deployed in a centralized cloud, it builds advanced Machine Learning (ML) algorithms using long-term RAN data to define dynamic and adaptive policies to control and optimize network performance and configuration management decisions. Non-RT RIC can also be used in existing legacy networks, adding another performance layer through ML for policy control.
- Near-real time (Near-RT) O-RIC — Deployed at or towards the edge, it uses a low latency control loop that optimizes RAN activity at both the cell and individual user equipment (UE) level by hosting trained Artificial Intelligence (AI) and ML applications to infer and control Open RAN elements in near-RT. The near-RT O-RIC intelligently optimizes UE-level control-plane call processing and user-plane data transfer decisions. This level of granularity is not available in SON.
Mavenir’s O-RIC is a business results tool, that enables intent-based decisions by setting granular performance targets—at the cell or even individual UE level—to generate business outcomes, such as the generation of additional revenue (enabling an SLA that generates a premium service), the reduction in network cost through the optimization of resources (energy savings, spectral efficiency, etc.), or the improvement of the end user experience (by improving throughput, reducing latency and connection drops, and expanding coverage). The NIaaS signature framework of Mavenir’s RIC accomplishes this goal by offering fine-grained predictive intelligence and advanced analytics about the RAN to third party applications (rApps and xApps), integrated with Mavenir’s O-RIC, towards optimizing the network performance.
Mavenir’s O-RIC shifts control from the vendor ecosystem to the operator by delivering an Open API framework that allows the implementation of standards-based rApps and xApps for different business outcomes, such as energy savings, traffic steering, massive MIMO optimization, spectral efficiency improvements, and RAN slice assurance. Proprietary radio access solutions limit the choice to what their vendor has to offer and open up the network to fine-grained per user data-driven optimization. With Mavenir’s RIC, applications can be developed by an in-house team or purchased in an "app store" from any Open RAN compliant third party.
"Creating real business value for next-generation Open RAN networks requires deep telco domain expertise and a disruptive approach to network intelligence," said Brandon Larson, SVP & GM of the Multimedia Business Unit at Mavenir. "As a pioneer in cloud-native solutions at a massive scale, Mavenir is leading the way with award-winning Open vRAN solutions, layered with O-RIC AI and ML algorithms and applications, which create operator customizable business outcomes based on target objectives to solve unique business problems and give control of the network back to the CSP."
Mavenir's O-RIC offers unparalleled benefits in terms of (i) Network performance, (ii) User Experience, (iii) Reduced TCO, (iv) Simplified cloud-native deployments, (v) new revenue sources, etc.
For more information visit the Mavenir Open RAN Intelligent Controller page.
Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005022/en/
Contact information
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
